nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—HTR1F—trigeminal nerve—bone cancer	0.112	0.223	CbGeAlD
Rizatriptan—HTR1B—dura mater—bone cancer	0.106	0.212	CbGeAlD
Rizatriptan—HTR1D—dura mater—bone cancer	0.103	0.205	CbGeAlD
Rizatriptan—HTR1B—trigeminal nerve—bone cancer	0.0457	0.0912	CbGeAlD
Rizatriptan—HTR1D—trigeminal nerve—bone cancer	0.0442	0.0883	CbGeAlD
Rizatriptan—HTR1B—cranial nerve—bone cancer	0.0326	0.065	CbGeAlD
Rizatriptan—HTR1D—cranial nerve—bone cancer	0.0315	0.0629	CbGeAlD
Rizatriptan—HTR1D—connective tissue—bone cancer	0.0065	0.013	CbGeAlD
Rizatriptan—MAOA—connective tissue—bone cancer	0.00495	0.00989	CbGeAlD
Rizatriptan—HTR1B—spinal cord—bone cancer	0.00445	0.00889	CbGeAlD
Rizatriptan—HTR1A—spinal cord—bone cancer	0.00359	0.00717	CbGeAlD
Rizatriptan—MAOA—tendon—bone cancer	0.0034	0.0068	CbGeAlD
Rizatriptan—MAOA—spinal cord—bone cancer	0.00328	0.00655	CbGeAlD
Rizatriptan—Photosensitivity—Doxorubicin—bone cancer	0.00177	0.0036	CcSEcCtD
Rizatriptan—Anaphylactoid reaction—Epirubicin—bone cancer	0.00173	0.00353	CcSEcCtD
Rizatriptan—Eye pain—Doxorubicin—bone cancer	0.00172	0.0035	CcSEcCtD
Rizatriptan—Cerebrovascular accident—Epirubicin—bone cancer	0.00171	0.00349	CcSEcCtD
Rizatriptan—Irritability—Methotrexate—bone cancer	0.00171	0.00348	CcSEcCtD
Rizatriptan—Convulsion—Cisplatin—bone cancer	0.0017	0.00347	CcSEcCtD
Rizatriptan—Ataxia—Methotrexate—bone cancer	0.00168	0.00343	CcSEcCtD
Rizatriptan—Osteoarthritis—Epirubicin—bone cancer	0.00168	0.00342	CcSEcCtD
Rizatriptan—Myalgia—Cisplatin—bone cancer	0.00167	0.00341	CcSEcCtD
Rizatriptan—Anxiety—Cisplatin—bone cancer	0.00167	0.0034	CcSEcCtD
Rizatriptan—Hot flush—Doxorubicin—bone cancer	0.00166	0.00338	CcSEcCtD
Rizatriptan—Discomfort—Cisplatin—bone cancer	0.00165	0.00337	CcSEcCtD
Rizatriptan—Increased appetite—Doxorubicin—bone cancer	0.00165	0.00336	CcSEcCtD
Rizatriptan—Menopausal symptoms—Doxorubicin—bone cancer	0.00164	0.00335	CcSEcCtD
Rizatriptan—Face oedema—Epirubicin—bone cancer	0.00162	0.0033	CcSEcCtD
Rizatriptan—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00161	0.00329	CcSEcCtD
Rizatriptan—Anaphylactic shock—Cisplatin—bone cancer	0.0016	0.00327	CcSEcCtD
Rizatriptan—Oedema—Cisplatin—bone cancer	0.0016	0.00327	CcSEcCtD
Rizatriptan—Anaphylactoid reaction—Doxorubicin—bone cancer	0.0016	0.00327	CcSEcCtD
Rizatriptan—Cerebrovascular accident—Doxorubicin—bone cancer	0.00158	0.00323	CcSEcCtD
Rizatriptan—Ataxia—Epirubicin—bone cancer	0.00158	0.00321	CcSEcCtD
Rizatriptan—Nervous system disorder—Cisplatin—bone cancer	0.00157	0.00321	CcSEcCtD
Rizatriptan—Tachycardia—Cisplatin—bone cancer	0.00156	0.00319	CcSEcCtD
Rizatriptan—Dehydration—Epirubicin—bone cancer	0.00156	0.00318	CcSEcCtD
Rizatriptan—Osteoarthritis—Doxorubicin—bone cancer	0.00155	0.00316	CcSEcCtD
Rizatriptan—Hyperhidrosis—Cisplatin—bone cancer	0.00155	0.00316	CcSEcCtD
Rizatriptan—Anorexia—Cisplatin—bone cancer	0.00153	0.00312	CcSEcCtD
Rizatriptan—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00151	0.00308	CcSEcCtD
Rizatriptan—Nasopharyngitis—Epirubicin—bone cancer	0.0015	0.00306	CcSEcCtD
Rizatriptan—Face oedema—Doxorubicin—bone cancer	0.0015	0.00305	CcSEcCtD
Rizatriptan—Abdominal discomfort—Methotrexate—bone cancer	0.00148	0.00303	CcSEcCtD
Rizatriptan—Gastritis—Epirubicin—bone cancer	0.00148	0.00302	CcSEcCtD
Rizatriptan—Muscular weakness—Epirubicin—bone cancer	0.00148	0.00301	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00146	0.00298	CcSEcCtD
Rizatriptan—Abdominal distension—Epirubicin—bone cancer	0.00146	0.00297	CcSEcCtD
Rizatriptan—Ataxia—Doxorubicin—bone cancer	0.00146	0.00297	CcSEcCtD
Rizatriptan—Dysphagia—Epirubicin—bone cancer	0.00145	0.00295	CcSEcCtD
Rizatriptan—Dysuria—Methotrexate—bone cancer	0.00145	0.00295	CcSEcCtD
Rizatriptan—Dehydration—Doxorubicin—bone cancer	0.00144	0.00294	CcSEcCtD
Rizatriptan—Paraesthesia—Cisplatin—bone cancer	0.00144	0.00294	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Methotrexate—bone cancer	0.00144	0.00293	CcSEcCtD
Rizatriptan—Dyspnoea—Cisplatin—bone cancer	0.00143	0.00292	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Methotrexate—bone cancer	0.00141	0.00288	CcSEcCtD
Rizatriptan—Angina pectoris—Epirubicin—bone cancer	0.00141	0.00288	CcSEcCtD
Rizatriptan—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.0014	0.00285	CcSEcCtD
Rizatriptan—Decreased appetite—Cisplatin—bone cancer	0.00139	0.00284	CcSEcCtD
Rizatriptan—Nasopharyngitis—Doxorubicin—bone cancer	0.00139	0.00283	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Cisplatin—bone cancer	0.00138	0.00282	CcSEcCtD
Rizatriptan—Gastritis—Doxorubicin—bone cancer	0.00137	0.0028	CcSEcCtD
Rizatriptan—Pain—Cisplatin—bone cancer	0.00137	0.0028	CcSEcCtD
Rizatriptan—Muscular weakness—Doxorubicin—bone cancer	0.00137	0.00279	CcSEcCtD
Rizatriptan—Dysuria—Epirubicin—bone cancer	0.00135	0.00276	CcSEcCtD
Rizatriptan—Abdominal distension—Doxorubicin—bone cancer	0.00135	0.00275	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Epirubicin—bone cancer	0.00135	0.00274	CcSEcCtD
Rizatriptan—Dysphagia—Doxorubicin—bone cancer	0.00134	0.00273	CcSEcCtD
Rizatriptan—Pollakiuria—Epirubicin—bone cancer	0.00134	0.00273	CcSEcCtD
Rizatriptan—Sweating—Methotrexate—bone cancer	0.00132	0.0027	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Epirubicin—bone cancer	0.00132	0.0027	CcSEcCtD
Rizatriptan—Feeling abnormal—Cisplatin—bone cancer	0.00132	0.00269	CcSEcCtD
Rizatriptan—Angina pectoris—Doxorubicin—bone cancer	0.00131	0.00266	CcSEcCtD
Rizatriptan—Epistaxis—Methotrexate—bone cancer	0.0013	0.00265	CcSEcCtD
Rizatriptan—Body temperature increased—Cisplatin—bone cancer	0.00127	0.00258	CcSEcCtD
Rizatriptan—Dysuria—Doxorubicin—bone cancer	0.00125	0.00255	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00125	0.00254	CcSEcCtD
Rizatriptan—Sweating—Epirubicin—bone cancer	0.00124	0.00252	CcSEcCtD
Rizatriptan—Pollakiuria—Doxorubicin—bone cancer	0.00124	0.00252	CcSEcCtD
Rizatriptan—Pharyngitis—Methotrexate—bone cancer	0.00123	0.00251	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Doxorubicin—bone cancer	0.00122	0.00249	CcSEcCtD
Rizatriptan—Epistaxis—Epirubicin—bone cancer	0.00122	0.00248	CcSEcCtD
Rizatriptan—Hypersensitivity—Cisplatin—bone cancer	0.00118	0.00241	CcSEcCtD
Rizatriptan—Bradycardia—Epirubicin—bone cancer	0.00118	0.00241	CcSEcCtD
Rizatriptan—Tinnitus—Methotrexate—bone cancer	0.00115	0.00235	CcSEcCtD
Rizatriptan—Hypoaesthesia—Epirubicin—bone cancer	0.00115	0.00235	CcSEcCtD
Rizatriptan—Asthenia—Cisplatin—bone cancer	0.00115	0.00235	CcSEcCtD
Rizatriptan—Pharyngitis—Epirubicin—bone cancer	0.00115	0.00235	CcSEcCtD
Rizatriptan—Sweating—Doxorubicin—bone cancer	0.00115	0.00234	CcSEcCtD
Rizatriptan—Epistaxis—Doxorubicin—bone cancer	0.00113	0.0023	CcSEcCtD
Rizatriptan—Angiopathy—Methotrexate—bone cancer	0.00112	0.00229	CcSEcCtD
Rizatriptan—Chills—Methotrexate—bone cancer	0.00111	0.00227	CcSEcCtD
Rizatriptan—Diarrhoea—Cisplatin—bone cancer	0.0011	0.00224	CcSEcCtD
Rizatriptan—Bradycardia—Doxorubicin—bone cancer	0.00109	0.00223	CcSEcCtD
Rizatriptan—Mental disorder—Methotrexate—bone cancer	0.00108	0.00221	CcSEcCtD
Rizatriptan—Tinnitus—Epirubicin—bone cancer	0.00108	0.0022	CcSEcCtD
Rizatriptan—Erythema—Methotrexate—bone cancer	0.00108	0.0022	CcSEcCtD
Rizatriptan—Flushing—Epirubicin—bone cancer	0.00108	0.00219	CcSEcCtD
Rizatriptan—Hypoaesthesia—Doxorubicin—bone cancer	0.00107	0.00218	CcSEcCtD
Rizatriptan—Pharyngitis—Doxorubicin—bone cancer	0.00106	0.00217	CcSEcCtD
Rizatriptan—Dysgeusia—Methotrexate—bone cancer	0.00106	0.00215	CcSEcCtD
Rizatriptan—Angiopathy—Epirubicin—bone cancer	0.00105	0.00214	CcSEcCtD
Rizatriptan—Chills—Epirubicin—bone cancer	0.00104	0.00212	CcSEcCtD
Rizatriptan—Arrhythmia—Epirubicin—bone cancer	0.00104	0.00211	CcSEcCtD
Rizatriptan—Vomiting—Cisplatin—bone cancer	0.00102	0.00208	CcSEcCtD
Rizatriptan—Vision blurred—Methotrexate—bone cancer	0.00102	0.00207	CcSEcCtD
Rizatriptan—Mental disorder—Epirubicin—bone cancer	0.00102	0.00207	CcSEcCtD
Rizatriptan—Rash—Cisplatin—bone cancer	0.00101	0.00206	CcSEcCtD
Rizatriptan—Dermatitis—Cisplatin—bone cancer	0.00101	0.00206	CcSEcCtD
Rizatriptan—Erythema—Epirubicin—bone cancer	0.00101	0.00206	CcSEcCtD
Rizatriptan—Tinnitus—Doxorubicin—bone cancer	0.001	0.00204	CcSEcCtD
Rizatriptan—Flushing—Doxorubicin—bone cancer	0.000995	0.00203	CcSEcCtD
Rizatriptan—Flatulence—Epirubicin—bone cancer	0.000994	0.00203	CcSEcCtD
Rizatriptan—Tension—Epirubicin—bone cancer	0.00099	0.00202	CcSEcCtD
Rizatriptan—Dysgeusia—Epirubicin—bone cancer	0.000988	0.00201	CcSEcCtD
Rizatriptan—Nervousness—Epirubicin—bone cancer	0.00098	0.002	CcSEcCtD
Rizatriptan—Angiopathy—Doxorubicin—bone cancer	0.000973	0.00198	CcSEcCtD
Rizatriptan—Muscle spasms—Epirubicin—bone cancer	0.00097	0.00198	CcSEcCtD
Rizatriptan—Vertigo—Methotrexate—bone cancer	0.000969	0.00198	CcSEcCtD
Rizatriptan—Chills—Doxorubicin—bone cancer	0.000962	0.00196	CcSEcCtD
Rizatriptan—Arrhythmia—Doxorubicin—bone cancer	0.000958	0.00195	CcSEcCtD
Rizatriptan—Nausea—Cisplatin—bone cancer	0.000952	0.00194	CcSEcCtD
Rizatriptan—Vision blurred—Epirubicin—bone cancer	0.000951	0.00194	CcSEcCtD
Rizatriptan—Cough—Methotrexate—bone cancer	0.000941	0.00192	CcSEcCtD
Rizatriptan—Mental disorder—Doxorubicin—bone cancer	0.000939	0.00192	CcSEcCtD
Rizatriptan—Convulsion—Methotrexate—bone cancer	0.000934	0.0019	CcSEcCtD
Rizatriptan—Erythema—Doxorubicin—bone cancer	0.000933	0.0019	CcSEcCtD
Rizatriptan—Agitation—Epirubicin—bone cancer	0.000927	0.00189	CcSEcCtD
Rizatriptan—Almotriptan—CYP3A4—bone cancer	0.000921	1	CrCbGaD
Rizatriptan—Flatulence—Doxorubicin—bone cancer	0.00092	0.00188	CcSEcCtD
Rizatriptan—Myalgia—Methotrexate—bone cancer	0.000918	0.00187	CcSEcCtD
Rizatriptan—Chest pain—Methotrexate—bone cancer	0.000918	0.00187	CcSEcCtD
Rizatriptan—Arthralgia—Methotrexate—bone cancer	0.000918	0.00187	CcSEcCtD
Rizatriptan—Tension—Doxorubicin—bone cancer	0.000916	0.00187	CcSEcCtD
Rizatriptan—Dysgeusia—Doxorubicin—bone cancer	0.000914	0.00186	CcSEcCtD
Rizatriptan—Discomfort—Methotrexate—bone cancer	0.000907	0.00185	CcSEcCtD
Rizatriptan—Nervousness—Doxorubicin—bone cancer	0.000907	0.00185	CcSEcCtD
Rizatriptan—Vertigo—Epirubicin—bone cancer	0.000906	0.00185	CcSEcCtD
Rizatriptan—Syncope—Epirubicin—bone cancer	0.000905	0.00185	CcSEcCtD
Rizatriptan—Muscle spasms—Doxorubicin—bone cancer	0.000897	0.00183	CcSEcCtD
Rizatriptan—Palpitations—Epirubicin—bone cancer	0.000892	0.00182	CcSEcCtD
Rizatriptan—Confusional state—Methotrexate—bone cancer	0.000887	0.00181	CcSEcCtD
Rizatriptan—Loss of consciousness—Epirubicin—bone cancer	0.000887	0.00181	CcSEcCtD
Rizatriptan—Cough—Epirubicin—bone cancer	0.00088	0.0018	CcSEcCtD
Rizatriptan—Anaphylactic shock—Methotrexate—bone cancer	0.00088	0.00179	CcSEcCtD
Rizatriptan—Vision blurred—Doxorubicin—bone cancer	0.00088	0.00179	CcSEcCtD
Rizatriptan—Convulsion—Epirubicin—bone cancer	0.000874	0.00178	CcSEcCtD
Rizatriptan—Hypertension—Epirubicin—bone cancer	0.000871	0.00178	CcSEcCtD
Rizatriptan—Nervous system disorder—Methotrexate—bone cancer	0.000863	0.00176	CcSEcCtD
Rizatriptan—Myalgia—Epirubicin—bone cancer	0.000859	0.00175	CcSEcCtD
Rizatriptan—Chest pain—Epirubicin—bone cancer	0.000859	0.00175	CcSEcCtD
Rizatriptan—Arthralgia—Epirubicin—bone cancer	0.000859	0.00175	CcSEcCtD
Rizatriptan—Agitation—Doxorubicin—bone cancer	0.000858	0.00175	CcSEcCtD
Rizatriptan—Anxiety—Epirubicin—bone cancer	0.000856	0.00175	CcSEcCtD
Rizatriptan—Hyperhidrosis—Methotrexate—bone cancer	0.000851	0.00173	CcSEcCtD
Rizatriptan—Discomfort—Epirubicin—bone cancer	0.000849	0.00173	CcSEcCtD
Rizatriptan—Dry mouth—Epirubicin—bone cancer	0.00084	0.00171	CcSEcCtD
Rizatriptan—Vertigo—Doxorubicin—bone cancer	0.000839	0.00171	CcSEcCtD
Rizatriptan—Anorexia—Methotrexate—bone cancer	0.000839	0.00171	CcSEcCtD
Rizatriptan—Syncope—Doxorubicin—bone cancer	0.000837	0.00171	CcSEcCtD
Rizatriptan—Confusional state—Epirubicin—bone cancer	0.00083	0.00169	CcSEcCtD
Rizatriptan—Palpitations—Doxorubicin—bone cancer	0.000825	0.00168	CcSEcCtD
Rizatriptan—Oedema—Epirubicin—bone cancer	0.000823	0.00168	CcSEcCtD
Rizatriptan—Anaphylactic shock—Epirubicin—bone cancer	0.000823	0.00168	CcSEcCtD
Rizatriptan—Loss of consciousness—Doxorubicin—bone cancer	0.00082	0.00167	CcSEcCtD
Rizatriptan—Cough—Doxorubicin—bone cancer	0.000815	0.00166	CcSEcCtD
Rizatriptan—Shock—Epirubicin—bone cancer	0.00081	0.00165	CcSEcCtD
Rizatriptan—Convulsion—Doxorubicin—bone cancer	0.000809	0.00165	CcSEcCtD
Rizatriptan—Nervous system disorder—Epirubicin—bone cancer	0.000807	0.00165	CcSEcCtD
Rizatriptan—Hypertension—Doxorubicin—bone cancer	0.000806	0.00164	CcSEcCtD
Rizatriptan—Tachycardia—Epirubicin—bone cancer	0.000804	0.00164	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000802	0.00163	CcSEcCtD
Rizatriptan—Hyperhidrosis—Epirubicin—bone cancer	0.000796	0.00162	CcSEcCtD
Rizatriptan—Insomnia—Methotrexate—bone cancer	0.000796	0.00162	CcSEcCtD
Rizatriptan—Myalgia—Doxorubicin—bone cancer	0.000795	0.00162	CcSEcCtD
Rizatriptan—Chest pain—Doxorubicin—bone cancer	0.000795	0.00162	CcSEcCtD
Rizatriptan—Arthralgia—Doxorubicin—bone cancer	0.000795	0.00162	CcSEcCtD
Rizatriptan—Anxiety—Doxorubicin—bone cancer	0.000792	0.00162	CcSEcCtD
Rizatriptan—Paraesthesia—Methotrexate—bone cancer	0.00079	0.00161	CcSEcCtD
Rizatriptan—Discomfort—Doxorubicin—bone cancer	0.000785	0.0016	CcSEcCtD
Rizatriptan—Anorexia—Epirubicin—bone cancer	0.000785	0.0016	CcSEcCtD
Rizatriptan—Dyspnoea—Methotrexate—bone cancer	0.000784	0.0016	CcSEcCtD
Rizatriptan—Somnolence—Methotrexate—bone cancer	0.000782	0.0016	CcSEcCtD
Rizatriptan—Dry mouth—Doxorubicin—bone cancer	0.000777	0.00159	CcSEcCtD
Rizatriptan—Dyspepsia—Methotrexate—bone cancer	0.000774	0.00158	CcSEcCtD
Rizatriptan—Confusional state—Doxorubicin—bone cancer	0.000768	0.00157	CcSEcCtD
Rizatriptan—Decreased appetite—Methotrexate—bone cancer	0.000765	0.00156	CcSEcCtD
Rizatriptan—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.000764	0.0975	CbGpPWpGaD
Rizatriptan—Oedema—Doxorubicin—bone cancer	0.000762	0.00155	CcSEcCtD
Rizatriptan—Anaphylactic shock—Doxorubicin—bone cancer	0.000762	0.00155	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Methotrexate—bone cancer	0.00076	0.00155	CcSEcCtD
Rizatriptan—Fatigue—Methotrexate—bone cancer	0.000759	0.00155	CcSEcCtD
Rizatriptan—Pain—Methotrexate—bone cancer	0.000752	0.00153	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00075	0.00153	CcSEcCtD
Rizatriptan—Shock—Doxorubicin—bone cancer	0.00075	0.00153	CcSEcCtD
Rizatriptan—Nervous system disorder—Doxorubicin—bone cancer	0.000747	0.00152	CcSEcCtD
Rizatriptan—Insomnia—Epirubicin—bone cancer	0.000745	0.00152	CcSEcCtD
Rizatriptan—Tachycardia—Doxorubicin—bone cancer	0.000744	0.00152	CcSEcCtD
Rizatriptan—Paraesthesia—Epirubicin—bone cancer	0.000739	0.00151	CcSEcCtD
Rizatriptan—Hyperhidrosis—Doxorubicin—bone cancer	0.000736	0.0015	CcSEcCtD
Rizatriptan—Dyspnoea—Epirubicin—bone cancer	0.000734	0.0015	CcSEcCtD
Rizatriptan—Somnolence—Epirubicin—bone cancer	0.000732	0.00149	CcSEcCtD
Rizatriptan—Anorexia—Doxorubicin—bone cancer	0.000726	0.00148	CcSEcCtD
Rizatriptan—Feeling abnormal—Methotrexate—bone cancer	0.000725	0.00148	CcSEcCtD
Rizatriptan—Dyspepsia—Epirubicin—bone cancer	0.000725	0.00148	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Methotrexate—bone cancer	0.000719	0.00147	CcSEcCtD
Rizatriptan—Decreased appetite—Epirubicin—bone cancer	0.000716	0.00146	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Epirubicin—bone cancer	0.000711	0.00145	CcSEcCtD
Rizatriptan—Fatigue—Epirubicin—bone cancer	0.00071	0.00145	CcSEcCtD
Rizatriptan—Pain—Epirubicin—bone cancer	0.000704	0.00144	CcSEcCtD
Rizatriptan—Constipation—Epirubicin—bone cancer	0.000704	0.00144	CcSEcCtD
Rizatriptan—Urticaria—Methotrexate—bone cancer	0.000699	0.00143	CcSEcCtD
Rizatriptan—Body temperature increased—Methotrexate—bone cancer	0.000696	0.00142	CcSEcCtD
Rizatriptan—Abdominal pain—Methotrexate—bone cancer	0.000696	0.00142	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000694	0.00142	CcSEcCtD
Rizatriptan—Insomnia—Doxorubicin—bone cancer	0.000689	0.00141	CcSEcCtD
Rizatriptan—Paraesthesia—Doxorubicin—bone cancer	0.000684	0.0014	CcSEcCtD
Rizatriptan—Dyspnoea—Doxorubicin—bone cancer	0.000679	0.00139	CcSEcCtD
Rizatriptan—Feeling abnormal—Epirubicin—bone cancer	0.000679	0.00138	CcSEcCtD
Rizatriptan—Somnolence—Doxorubicin—bone cancer	0.000677	0.00138	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Epirubicin—bone cancer	0.000673	0.00137	CcSEcCtD
Rizatriptan—Dyspepsia—Doxorubicin—bone cancer	0.000671	0.00137	CcSEcCtD
Rizatriptan—Decreased appetite—Doxorubicin—bone cancer	0.000662	0.00135	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000658	0.00134	CcSEcCtD
Rizatriptan—Fatigue—Doxorubicin—bone cancer	0.000657	0.00134	CcSEcCtD
Rizatriptan—Urticaria—Epirubicin—bone cancer	0.000654	0.00133	CcSEcCtD
Rizatriptan—Constipation—Doxorubicin—bone cancer	0.000651	0.00133	CcSEcCtD
Rizatriptan—Pain—Doxorubicin—bone cancer	0.000651	0.00133	CcSEcCtD
Rizatriptan—Body temperature increased—Epirubicin—bone cancer	0.000651	0.00133	CcSEcCtD
Rizatriptan—Abdominal pain—Epirubicin—bone cancer	0.000651	0.00133	CcSEcCtD
Rizatriptan—Hypersensitivity—Methotrexate—bone cancer	0.000648	0.00132	CcSEcCtD
Rizatriptan—Asthenia—Methotrexate—bone cancer	0.000631	0.00129	CcSEcCtD
Rizatriptan—Feeling abnormal—Doxorubicin—bone cancer	0.000628	0.00128	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Doxorubicin—bone cancer	0.000623	0.00127	CcSEcCtD
Rizatriptan—Pruritus—Methotrexate—bone cancer	0.000622	0.00127	CcSEcCtD
Rizatriptan—Hypersensitivity—Epirubicin—bone cancer	0.000607	0.00124	CcSEcCtD
Rizatriptan—Urticaria—Doxorubicin—bone cancer	0.000605	0.00123	CcSEcCtD
Rizatriptan—Body temperature increased—Doxorubicin—bone cancer	0.000602	0.00123	CcSEcCtD
Rizatriptan—Abdominal pain—Doxorubicin—bone cancer	0.000602	0.00123	CcSEcCtD
Rizatriptan—Diarrhoea—Methotrexate—bone cancer	0.000602	0.00123	CcSEcCtD
Rizatriptan—Asthenia—Epirubicin—bone cancer	0.000591	0.0012	CcSEcCtD
Rizatriptan—Pruritus—Epirubicin—bone cancer	0.000583	0.00119	CcSEcCtD
Rizatriptan—Dizziness—Methotrexate—bone cancer	0.000582	0.00119	CcSEcCtD
Rizatriptan—Diarrhoea—Epirubicin—bone cancer	0.000563	0.00115	CcSEcCtD
Rizatriptan—Hypersensitivity—Doxorubicin—bone cancer	0.000561	0.00114	CcSEcCtD
Rizatriptan—Vomiting—Methotrexate—bone cancer	0.000559	0.00114	CcSEcCtD
Rizatriptan—Rash—Methotrexate—bone cancer	0.000555	0.00113	CcSEcCtD
Rizatriptan—Dermatitis—Methotrexate—bone cancer	0.000554	0.00113	CcSEcCtD
Rizatriptan—Headache—Methotrexate—bone cancer	0.000551	0.00112	CcSEcCtD
Rizatriptan—Asthenia—Doxorubicin—bone cancer	0.000547	0.00111	CcSEcCtD
Rizatriptan—Dizziness—Epirubicin—bone cancer	0.000544	0.00111	CcSEcCtD
Rizatriptan—Pruritus—Doxorubicin—bone cancer	0.000539	0.0011	CcSEcCtD
Rizatriptan—Vomiting—Epirubicin—bone cancer	0.000524	0.00107	CcSEcCtD
Rizatriptan—Nausea—Methotrexate—bone cancer	0.000523	0.00107	CcSEcCtD
Rizatriptan—Diarrhoea—Doxorubicin—bone cancer	0.000521	0.00106	CcSEcCtD
Rizatriptan—Rash—Epirubicin—bone cancer	0.000519	0.00106	CcSEcCtD
Rizatriptan—Dermatitis—Epirubicin—bone cancer	0.000519	0.00106	CcSEcCtD
Rizatriptan—Headache—Epirubicin—bone cancer	0.000516	0.00105	CcSEcCtD
Rizatriptan—Dizziness—Doxorubicin—bone cancer	0.000504	0.00103	CcSEcCtD
Rizatriptan—Nausea—Epirubicin—bone cancer	0.000489	0.000997	CcSEcCtD
Rizatriptan—Vomiting—Doxorubicin—bone cancer	0.000484	0.000988	CcSEcCtD
Rizatriptan—Rash—Doxorubicin—bone cancer	0.00048	0.00098	CcSEcCtD
Rizatriptan—Dermatitis—Doxorubicin—bone cancer	0.00048	0.000979	CcSEcCtD
Rizatriptan—Headache—Doxorubicin—bone cancer	0.000477	0.000973	CcSEcCtD
Rizatriptan—Nausea—Doxorubicin—bone cancer	0.000453	0.000923	CcSEcCtD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—FEV—bone cancer	0.000321	0.041	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Other—GRM1—bone cancer	0.000298	0.038	CbGpPWpGaD
Rizatriptan—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00028	0.0358	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—FEV—bone cancer	0.000273	0.0348	CbGpPWpGaD
Rizatriptan—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000251	0.032	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Other—SMO—bone cancer	0.00021	0.0268	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—GRM4—bone cancer	0.000161	0.0205	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—RGS1—bone cancer	0.000161	0.0205	CbGpPWpGaD
Rizatriptan—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000145	0.0185	CbGpPWpGaD
Rizatriptan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000136	0.0173	CbGpPWpGaD
Rizatriptan—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000132	0.0168	CbGpPWpGaD
Rizatriptan—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000126	0.0161	CbGpPWpGaD
Rizatriptan—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000121	0.0155	CbGpPWpGaD
Rizatriptan—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000116	0.0149	CbGpPWpGaD
Rizatriptan—MAOA—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00011	0.0141	CbGpPWpGaD
Rizatriptan—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000108	0.0138	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—GRM4—bone cancer	0.000103	0.0131	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—RGS1—bone cancer	0.000103	0.0131	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—RGS1—bone cancer	0.000101	0.0129	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—GRM4—bone cancer	0.000101	0.0129	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—GRM4—bone cancer	9.74e-05	0.0124	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—GRM1—bone cancer	8.44e-05	0.0108	CbGpPWpGaD
Rizatriptan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	7.92e-05	0.0101	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—RGS1—bone cancer	7.67e-05	0.00979	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—GRM4—bone cancer	7.67e-05	0.00979	CbGpPWpGaD
Rizatriptan—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	6.82e-05	0.00871	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—GRM4—bone cancer	6.23e-05	0.00795	CbGpPWpGaD
Rizatriptan—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	6.22e-05	0.00794	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—GRM4—bone cancer	6.1e-05	0.00778	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—SMO—bone cancer	5.95e-05	0.00759	CbGpPWpGaD
Rizatriptan—MAOA—Biological oxidations—CYP3A4—bone cancer	5.87e-05	0.00749	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—GRM4—bone cancer	5.5e-05	0.00703	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—RGS1—bone cancer	5.5e-05	0.00703	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—GRM1—bone cancer	5.4e-05	0.00689	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—GRM1—bone cancer	5.29e-05	0.00675	CbGpPWpGaD
Rizatriptan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	5.03e-05	0.00642	CbGpPWpGaD
Rizatriptan—MAOA—Biological oxidations—GSTP1—bone cancer	5.02e-05	0.00641	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—GRM4—bone cancer	5e-05	0.00638	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—RGS1—bone cancer	5e-05	0.00638	CbGpPWpGaD
Rizatriptan—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	4.96e-05	0.00633	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—GRM1—bone cancer	4.77e-05	0.00609	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—GRM4—bone cancer	4.64e-05	0.00593	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—GRM1—bone cancer	4.33e-05	0.00553	CbGpPWpGaD
Rizatriptan—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.07e-05	0.0052	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—GRM1—bone cancer	4.03e-05	0.00514	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—SMO—bone cancer	3.8e-05	0.00486	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—SMO—bone cancer	3.72e-05	0.00476	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—GRM4—bone cancer	3.52e-05	0.00449	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—RGS1—bone cancer	3.52e-05	0.00449	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—NDUFA12—bone cancer	3.52e-05	0.00449	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—RGS1—bone cancer	3.45e-05	0.0044	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—GRM4—bone cancer	3.45e-05	0.0044	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	3.35e-05	0.00428	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—RGS1—bone cancer	3.2e-05	0.00408	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—GRM4—bone cancer	3.2e-05	0.00408	CbGpPWpGaD
Rizatriptan—CYP1A2—Phase II conjugation—GSTP1—bone cancer	3.16e-05	0.00404	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—RGS1—bone cancer	3.13e-05	0.00399	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—GRM4—bone cancer	3.13e-05	0.00399	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—GNA11—bone cancer	3.07e-05	0.00393	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—SMO—bone cancer	3.05e-05	0.0039	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—GRM1—bone cancer	3.05e-05	0.0039	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—GRM1—bone cancer	2.99e-05	0.00381	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—RGS1—bone cancer	2.95e-05	0.00377	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—GRM4—bone cancer	2.95e-05	0.00377	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—NT5C3A—bone cancer	2.91e-05	0.00372	CbGpPWpGaD
Rizatriptan—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	2.86e-05	0.00365	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—BRAF—bone cancer	2.85e-05	0.00364	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—SMO—bone cancer	2.84e-05	0.00362	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—GNA11—bone cancer	2.79e-05	0.00356	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—IL3—bone cancer	2.79e-05	0.00356	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—GRM1—bone cancer	2.77e-05	0.00354	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	2.75e-05	0.00352	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—GRM1—bone cancer	2.71e-05	0.00346	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—GRM4—bone cancer	2.62e-05	0.00335	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—RGS1—bone cancer	2.62e-05	0.00335	CbGpPWpGaD
Rizatriptan—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	2.58e-05	0.00329	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—GRM1—bone cancer	2.56e-05	0.00327	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—JUN—bone cancer	2.53e-05	0.00324	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—IL3—bone cancer	2.53e-05	0.00323	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	2.48e-05	0.00317	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—MDM2—bone cancer	2.39e-05	0.00305	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—RGS1—bone cancer	2.38e-05	0.00304	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—GRM4—bone cancer	2.38e-05	0.00304	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—GRM1—bone cancer	2.28e-05	0.00291	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—BRAF—bone cancer	2.19e-05	0.00279	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—CYP3A4—bone cancer	2.16e-05	0.00276	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—JUN—bone cancer	2.15e-05	0.00275	CbGpPWpGaD
Rizatriptan—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	2.13e-05	0.00272	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—GRM1—bone cancer	2.07e-05	0.00264	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—GNA11—bone cancer	1.97e-05	0.00251	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	1.95e-05	0.00249	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	1.95e-05	0.00249	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—SMO—bone cancer	1.95e-05	0.00249	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—GNA11—bone cancer	1.93e-05	0.00246	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—SMO—bone cancer	1.91e-05	0.00244	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—GRM4—bone cancer	1.89e-05	0.00241	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—RGS1—bone cancer	1.89e-05	0.00241	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—GSTP1—bone cancer	1.85e-05	0.00236	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—RGS1—bone cancer	1.85e-05	0.00236	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—GRM4—bone cancer	1.85e-05	0.00236	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—MDM2—bone cancer	1.83e-05	0.00234	CbGpPWpGaD
Rizatriptan—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	1.83e-05	0.00233	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—SMO—bone cancer	1.8e-05	0.0023	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—GNA11—bone cancer	1.79e-05	0.00228	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—IL3—bone cancer	1.78e-05	0.00228	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—GNA11—bone cancer	1.75e-05	0.00223	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—IL3—bone cancer	1.75e-05	0.00223	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—GNA11—bone cancer	1.65e-05	0.00211	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—GRM1—bone cancer	1.64e-05	0.00209	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—IL3—bone cancer	1.62e-05	0.00207	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—GRM1—bone cancer	1.6e-05	0.00205	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—IL3—bone cancer	1.58e-05	0.00202	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—ATF1—bone cancer	1.53e-05	0.00196	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IL3—bone cancer	1.5e-05	0.00191	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—GNA11—bone cancer	1.47e-05	0.00187	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—SMO—bone cancer	1.46e-05	0.00186	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—GRM4—bone cancer	1.41e-05	0.0018	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—RGS1—bone cancer	1.41e-05	0.0018	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—GNA11—bone cancer	1.33e-05	0.0017	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—IL3—bone cancer	1.33e-05	0.0017	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NDUFA12—bone cancer	1.3e-05	0.00166	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TGFBR2—bone cancer	1.28e-05	0.00163	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—ENO2—bone cancer	1.28e-05	0.00163	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—GRM1—bone cancer	1.22e-05	0.00156	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—IL3—bone cancer	1.21e-05	0.00154	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IGF1R—bone cancer	1.2e-05	0.00154	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—DHFR—bone cancer	1.18e-05	0.00151	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—SMO—bone cancer	1.15e-05	0.00147	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—SMO—bone cancer	1.13e-05	0.00144	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GNA11—bone cancer	1.11e-05	0.00141	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NT5C3A—bone cancer	1.07e-05	0.00137	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—GNA11—bone cancer	1.05e-05	0.00135	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—GNA11—bone cancer	1.03e-05	0.00132	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—CYP3A4—bone cancer	1e-05	0.00128	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—ATF1—bone cancer	9.81e-06	0.00125	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—ATF1—bone cancer	9.6e-06	0.00123	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IL3—bone cancer	9.56e-06	0.00122	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IL3—bone cancer	9.36e-06	0.0012	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—KIT—bone cancer	8.73e-06	0.00111	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—SMO—bone cancer	8.6e-06	0.0011	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GSTP1—bone cancer	8.58e-06	0.0011	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—BRAF—bone cancer	8.2e-06	0.00105	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TGFBR2—bone cancer	8.18e-06	0.00104	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TGFBR2—bone cancer	8.01e-06	0.00102	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—EGFR—bone cancer	7.95e-06	0.00101	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—GNA11—bone cancer	7.87e-06	0.001	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IGF1R—bone cancer	7.69e-06	0.000982	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IGF1R—bone cancer	7.53e-06	0.000962	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ATF1—bone cancer	7.31e-06	0.000934	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IL3—bone cancer	7.13e-06	0.000911	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MDM2—bone cancer	6.87e-06	0.000877	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TGFBR2—bone cancer	6.1e-06	0.000779	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—JUN—bone cancer	5.97e-06	0.000763	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MMP9—bone cancer	5.81e-06	0.000742	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IGF1R—bone cancer	5.74e-06	0.000733	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—KIT—bone cancer	5.58e-06	0.000712	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—KIT—bone cancer	5.46e-06	0.000698	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—BRAF—bone cancer	5.25e-06	0.00067	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—BRAF—bone cancer	5.14e-06	0.000656	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—EGFR—bone cancer	5.08e-06	0.000649	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—EGFR—bone cancer	4.98e-06	0.000636	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ENO2—bone cancer	4.71e-06	0.000601	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—EGFR—bone cancer	4.7e-06	0.0006	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PTGS2—bone cancer	4.45e-06	0.000568	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MDM2—bone cancer	4.39e-06	0.000561	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—DHFR—bone cancer	4.37e-06	0.000558	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MDM2—bone cancer	4.3e-06	0.000549	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—KIT—bone cancer	4.16e-06	0.000531	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GNA11—bone cancer	4.08e-06	0.000521	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TP53—bone cancer	3.94e-06	0.000503	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—BRAF—bone cancer	3.91e-06	0.000499	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—JUN—bone cancer	3.82e-06	0.000488	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—EGFR—bone cancer	3.79e-06	0.000484	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—JUN—bone cancer	3.74e-06	0.000478	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MMP9—bone cancer	3.72e-06	0.000474	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP3A4—bone cancer	3.7e-06	0.000472	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.68e-06	0.00047	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MMP9—bone cancer	3.64e-06	0.000465	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MDM2—bone cancer	3.28e-06	0.000419	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTP1—bone cancer	3.17e-06	0.000404	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—EGFR—bone cancer	3e-06	0.000383	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—EGFR—bone cancer	2.94e-06	0.000375	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—JUN—bone cancer	2.85e-06	0.000364	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MMP9—bone cancer	2.77e-06	0.000354	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TP53—bone cancer	2.52e-06	0.000322	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TP53—bone cancer	2.47e-06	0.000315	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—EGFR—bone cancer	2.24e-06	0.000286	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TP53—bone cancer	1.88e-06	0.00024	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PTGS2—bone cancer	1.64e-06	0.000209	CbGpPWpGaD
